Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719264 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
A Phase 2 study of Carcinoma and Adenocarcinoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT00719264 is a Phase 2 study of Carcinoma and Adenocarcinoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 365 participants, above the 242-participant average among 29 other Carcinoma trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00719264, a Phase 2 study of Carcinoma and Adenocarcinoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
Conditions Studied
Interventions
- DRUG bevacizumab
- DRUG RAD001(everolimus)
- DRUG interferon alfa-2a
Study Locations (20)
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Charleroi
- Novartis Investigative Site - Kortrijk
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Liège
California
- City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(3) - Duarte
- USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3 - Los Angeles
- University of California at Los Angeles Dept. of Hem/Oncology - Los Angeles
Rio Grande do Sul
- Novartis Investigative Site - Porto Alegre
- Novartis Investigative Site - Porto Alegre
São Paulo
- Novartis Investigative Site - Ribeirão Preto
- Novartis Investigative Site - Santo André
Arkansas
- Highlands Oncology Group Dept of Highlands Oncology Grp - Fayetteville
Michigan
- Karmanos Cancer Institute Dept.of KarmanosCancerInst (5) - Detroit
Nevada
- Nevada Cancer Institute Dept. of Nevada Cancer (3) - Las Vegas
Pennsylvania
- St. Luke's Hospital and Health Network St. Luke's Cancer Network - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2008-11-12 |
| Est. Completion | 2013-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719264
The ClinicalTrials.gov registry entry for NCT00719264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 242-participant average among 29 other Carcinoma trials with a reported enrollment target (51% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which bevacizumab is the first listed.
NCT00719264 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Rio Grande do Sul.
Frequently Asked Questions
What is clinical trial NCT00719264 about?
NCT00719264 is a clinical study titled "Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer". To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
What is the current status of trial NCT00719264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2008-11-12. Estimated completion is 2013-04-15.
What conditions does trial NCT00719264 study?
This clinical trial studies the following conditions: Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid.
What interventions are being tested in trial NCT00719264?
The interventions under investigation include: bevacizumab (DRUG), RAD001(everolimus) (DRUG), interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00719264?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00719264 being conducted?
This trial has 20 study locations across Arkansas, California, Michigan, Nevada, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
RECRUITING · Phase 2
-
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
ACTIVE NOT RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.